The current financial score of Indaptus Therapeutics Inc is 7.11. Its financial status is robust, and its operating efficiency is low.
The current valuation score of Indaptus Therapeutics Inc is 6.55. Its current P/E ratio is -0.28, which is -90.40% below the recent high of -0.03 and -712.63% above the recent low of -2.25.
No earnings forecast score is currently available for Indaptus Therapeutics Inc. The Biotechnology & Medical Research industry's average is 8.12. The average price target is 10.00, with a high of 10.00 and a low of 10.00.
The current price momentum score of Indaptus Therapeutics Inc is 9.31. Currently, the stock price is trading between the resistance level at 4.71 and the support level at 1.73, making it suitable for range-bound swing trading.
The current institutional shareholding score of Indaptus Therapeutics Inc is 3.00. The latest institutional shareholding proportion is 1.75%, representing a quarter-over-quarter decrease of 63.14%.
No risk assessment score is currently available for Indaptus Therapeutics Inc. The Biotechnology & Medical Research industry's average is 3.98. The company's beta value is 1.24. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.